Pieris Pharmaceuticals Investor Presentation — November 2022

Document content

SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGYCORPORATE PRESENTATION

Forward -Looking Statements

This presentation contains forward-looking statements asthat term isdefined inSection 27AoftheSecurities Actof1933 ,asamended,

and Section 21EoftheSecurities Exchange Actof1934, asamended. Statements inthispresentation that arenotpurely historical are

forward-looking statements .Such forward-looking statements include, among other things, whether PRS-220 willprovide aclinical benefit

inthetreatment ofIPFand PASC-related fibrosis; thereceipt ofroyalty and/or milestone payments provided forinourcollaboration

agreements; theexpected timing andpotential outcomes ofthereporting bytheCompany ofkeyclinical data from itsprograms ;references

tonovel technologies and methods and ourbusiness and product development plans, including theCompany's cash resources, the

advancement ofourproprietary and co-development programs into and through theclinic and theexpected timing forreporting data,

making IND filings orachieving other milestones related toourprograms, including elarekibep (PRS-060/AZD1402), PRS-344/S095012 ,

PRS-220 ,PRS-352/S 095025, PRS-342 /BOS -342, PRS-346 /SGN-BB228 and PRS-400; ourcontinued progress intheareas ofco-stim

bispecifics andinhaled therapeutics; thetherapeutic potential ofourAnticalin platform ;thepotential addressable market forourproduct

candidates ;andtheadvancement ofandfunding forourdevelopmental programs generally .Actual results could differ from those projected

inanyforward-looking statements duetonumerous factors .Such factors include, among others, ourability toraise theadditional funding

wewillneed tocontinue topursue ourbusiness andproduct development plans; theinherent uncertainties associated with developing new

products ortechnologies and operating asadevelopment stage company ;ourability todevelop, complete clinical trials for,obtain

approvals forandcommercialize anyofourproduct candidates, including ourability torecruit andenroll patients inourstudies ;ourability

toaddress therequests oftheU.S. Food andDrug Administration; competition intheindustry inwhich weoperate; delays ordisruptions

due toCOVID-19 orgeo-political issues, including theconflict inUkraine ;and market conditions. These forward -looking statements are

made asofthedate ofthispresentation, andweassume noobligation toupdate theforward-looking statements, ortoupdate thereasons

why actual results could differ from those projected intheforward-looking statements, except asrequired bylaw.Investors should consult

alloftheinformation setforth herein andshould also refer totheriskfactor disclosure setforth inthereports andother documents wefile